

Company Name: EIKEN CHEMICAL Co., Ltd.
 Representative: Morifumi Wada, President & CEO
 Securities code: 4549 (TSE 1st Section)

Revision of the Financial Forecast for the Fiscal Year Ending March 31, 2017

In light of recent trends in its business performance, Eiken Chemical Co., Ltd. announces that it has revised its financial forecast, which was announced on May 30, 2016. Details are as follows:

1. Revision of the consolidated financial forecast for the fiscal year ending March 31, 2017 (April 1, 2016 to March 31, 2017)

	Net sales	Operating income	Ordinary income	Net income attributable to shareholders of parent company	Net income per share
Previous forecast (A)	33,830	2,710	2,710	1,820	99.47
Revised forecast (B)	33,190	4,000	4,140	2,770	151.25
Change (B-A)	(640)	1,290	1,430	950	
Change ratio (%)	(1.9)	47.6	52.8	52.2	
Results for the previous fiscal year	32,163	3,536	3,570	2,429	132.85

2. Reason for Revision

1) Net sales

Domestic sales are as originally anticipated. Regarding overseas sales, although we anticipate an increase compared to the previous fiscal year, sales of reagents for fecal immunochemical testing will be sluggish, and we anticipate it will be lower than initially forecasted.

2) Income

It is expected that the income will increase significantly due to that the development cost -about 750 million yen- of the compact fully automated genetic testing device scheduled in the fourth quarter consolidated accounting period postponed to the second quarter of the fiscal year ending March 31 2018, and also the cost reduction by efficient use.

« Reference »

Revision of the non-consolidated financial forecast for the fiscal year ending March 31, 2017 (April 1, 2016 to March 31, 2017)

	Net sales	Operating income	Ordinary income	Net income	Net income per share
Previous forecast (A)	33,670	2,720	2,710	1,820	99.47
Revised forecast (B)	33,160	4,100	4,220	2,850	155.62
Change (B-A)	(510)	1,380	1,510	1,030	
Change ratio (%)	(1.5)	50.7	55.7	56.6	
Results for the previous fiscal year	32,135	3,556	3,607	2,466	134.88

Note: Forecast in this disclosure is made by management in light of information currently available. A number of factors could cause actual results to differ materially from those disclosed as above.